Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Baxter
Queensland Health
Merck
Chubb
AstraZeneca

Generated: July 17, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,447,104

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,447,104 protect, and when does it expire?

Patent 9,447,104 protects VITRAKVI and is included in two NDAs.

This patent has eighty patent family members in thirty-three countries.

Summary for Patent: 9,447,104
Title:Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Abstract: Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.
Inventor(s): Haas; Julia (Boulder, CO), Andrews; Steven W. (Boulder, CO), Jiang; Yutong (Boulder, CO), Zhang; Gan (Niwot, CO)
Assignee: Array BioPharma, Inc. (Boulder, CO)
Application Number:14/490,460
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,447,104
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 9,447,104

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare VITRAKVI larotrectinib CAPSULE;ORAL 210861-001 Nov 26, 2018 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION ➤ Sign Up
Bayer Hlthcare VITRAKVI larotrectinib CAPSULE;ORAL 210861-002 Nov 26, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION ➤ Sign Up
Bayer Healthcare VITRAKVI larotrectinib SOLUTION;ORAL 211710-001 Nov 26, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Queensland Health
Colorcon
Deloitte
Fish and Richardson
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.